MPP

Covid-19 development round-up: March 25, 2022

The state of the fight: 

Moderna shared new Phase 2/3 data supporting the use of Spikevax in children under age 6.
  Pfizer will supply UNICEF with up to 4 million Paxlovid courses in 2022.
  Boosters of mRNA vaccines continued to offer strong protection against severe Covid-19 outcomes.   AUTHORIZED VACCINES

 
Moderna claimed clinical trial success for its vaccine in children ages 6 months to under 6 years. An interim analysis of Phase 2/3 results showed…

Mentions:
Covid-19, vaccines, drugs, Moderna, BBIL, CanSino, CNBG, Sinopharm, Novavax, Sinovac, J&J, Gamaleya Institute, SII, WHO, Pfizer, BioNTech, SK Bioscience, Biovac, AstraZeneca, MPP, GSK, Vir, Gilead, Merck
Read more
Covid-19 development round-up: March 18, 2022

The state of the fight: 

Medicines Patent Pool sublicensed Pfizer’s Paxlovid to 35 generics manufacturers.
  Key WTO members reached a tentative agreement to waive some IP rights on Covid-19 vaccines.
  Moderna and Pfizer asked the U.S. FDA to authorize fourth doses of their respective jabs.   AUTHORIZED VACCINES

 
Medigen’s protein subunit vaccine (MVC-COV1901) offered similar safety and immunogenicity for adolescents as it did for adults, the Taipei-…

Mentions:
Covid-19, vaccines, drugs, Medigen, WHO, Moderna, Sinovac, AstraZeneca, FDA, Pfizer, BioNTech, CanSino, Anhui Longcom, Clover, SII, CureVac, GSK, WTO, COVAX, Gamaleya Institute, Gavi, Bio E, J&J, MPP, DNDi, Vir, Merck, Shionogi
Read more
ViiV sees blowback on PrEP access

When ViiV Healthcare announced last week that it would not pursue a voluntary licensing deal for its long-acting HIV prevention shot, blowback was swift. Advocacy groups cried foul. STAT remarked on the “surprise move.” The company backpedaled within days, but its updated statement continued to indicate the GSK subsidiary would remain the sole supplier of long-acting cabotegravir, “at least during the initial years.”

The statement that triggered the furor was less obliging: “voluntary…

Mentions:
ViiV, GSK, MSF, CHAI, HIV, PrEP, drugs, LMICs, market shaping, generics, patents, MPP
Read more
Covid-19 development round-up: March 4, 2022

The state of the fight: 

Pfizer/BioNTech’s Comirnaty appeared to offer only 12% effectiveness against Omicron in children ages 5-11.
  South Africa’s Biovac partnered with nine development institutions to boost local vaccine manufacturing capacity.
  Eli Lilly’s arthritis drug Olumiant reduced the risk of death by 13% in hospitalized Covid-19 patients.   AUTHORIZED VACCINES

 
Pfizer/BioNTech’s Comirnaty is far less protective against infection in children…

Mentions:
Covid-19, vaccines, drugs, Pfizer, BioNTech, Novavax, Sinovac, Valneva, FDA, Bharat Biotech, Inovio, Shionogi, CureVac, GSK, Biovac, Gamaleya Institute, WHO, MPP, Moderna, Bio Farma, ACT-A, EMA, J&J, AstraZeneca, Merck, Regeneron, Roche, Lilly, Gilead, DNDi
Read more
Covid-19 development round-up: February 4, 2022

The state of the fight: 

South Africa’s Afrigen has produced the first batch of its version of Moderna’s mRNA-based vaccine.
  Afrigen also secured a $45 million grant from the U.N.-backed Medicines Patent Pool.
  Moderna’s Spikevax notched full approval in the U.S.

REGULATORY UPDATES

 
Pfizer and BioNTech have begun rolling data submission for authorization of their Comirnaty shot in children between ages 6 months and 5 years “at the request” of…

Mentions:
Covid-19, vaccines, drugs, NIH, Moderna, FDA, CDC, Pfizer, BioNTech, Gamaleya Institute, Novavax, J&J, Sinovac, CNBG, Sinopharm, EuBiologics, WHO, Afrigen, Biovac, BioManguinhos, MPP, Zydus Cadila, Merck, Shionogi
Read more
Covid-19 development round-up: January 28, 2022

The state of the fight: 

Moderna and Pfizer/BioNTech launched trials of Omicron-specific vaccine candidates.
  India fully approved SII’s Covishield and Bharat Biotech’s Covaxin shots.
  CEPI tapped BioNet to develop a “variant-proof” pan-coronavirus mRNA-based vaccine.

AUTHORIZED VACCINES  

New data on rates of myocarditis following mRNA-based vaccination trickled in this week, highlighting an increased risk of the heart inflammation side effect in young…

Mentions:
Covid-19, vaccines, drugs, SII, BBIL, Pfizer, BioNTech, Moderna, J&J, Sinovac, CanSino, AstraZeneca, EMA, FDA, Sanofi, GSK, Novavax, Zydus Cadila, CEPI, COVAX, Gavi, MPP, Merck, Lilly, Regeneron, Roche, Gilead
Read more
Covid-19 development round-up: January 21, 2022

The state of the fight: 

African vaccine production advanced on multiple fronts, including the opening of a new manufacturing plant in South Africa.
  The COVAX AMC seeks an additional $5.2 billion this year.
  Merck will supply UNICEF with up to 3 million courses of molnupiravir in the first half of 2022.

AUTHORIZED VACCINES  

The Chilean health ministry released data on the Sinovac jab’s effectiveness in children. In kids ages 6-11, the topline numbers…

Mentions:
Covid-19, vaccines, drugs, WHO, Pfizer, BioNTech, Sinovac, EMA, Moderna, J&J, SII, BBIL, Novavax, Gamaleya Institute, Valneva, Clover, CEPI, IPD, COVAX, Gavi, Merck, UNICEF, MPP, GSK, Vir, Gilead, Regeneron, Roche
Read more
Covid-19 development round-up: December 23, 2021

The state of the fight: 

Oral antivirals from Pfizer and Merck notched U.S. FDA authorizations.
  Earlier use of remdesivir cut the risk of death or hospitalization by 87% in a new study.
  The Novavax vaccine secured a second WHO Emergency Use Listing.

AUTHORIZED VACCINES  

The AstraZeneca/Oxford vaccine starts waning in protection against serious illness within three months of the second dose, according to cohort studies in Brazil and Scotland published…

Mentions:
Covid-19, vaccines, drugs, AstraZeneca, IVI, CEPI, CNBG, Sinopharm, J&J, Janssen, Sinovac, Pfizer, BioNTech, Novavax, WHO, Moderna, SK Bio, EuBiologics, Gamaleya Institute, Valneva, SII, COVAX, BBIL, MPP, Merck, FDA, Gilead, GSK, Vir
Read more
Covid-19 development round-up: December 3, 2021

The state of the fight: 

A slew of vaccine manufacturers announced plans to tackle the Omicron variant.
  Aspen Pharmacare and J&J neared a deal that would let the South African manufacturer market its own version of the Janssen shot.
  Gavi’s board approved the alliance’s COVAX strategy for 2022.

AUTHORIZED VACCINES  


New research on the Pfizer/BioNTech shot affirmed its efficacy in younger people and its safety in older people.
 
…

Mentions:
Covid-19, vaccines, drugs, Pfizer, BioNTech, BBIL, FDA, Moderna, Gamaleya Institute, AstraZeneca, CNBG, Sinopharm, J&J, Janssen, Sinovac, Valneva, CEPI, Finlay Institute, Inovio, Novavax, WHO, EMA, Walvax, CureVac, Gavi, COVAX, MPP, Africa CDC, Merck, Lilly, Regeneron, Roche, GSK, Vir, Pfizer
Read more
Covid-19 development round-up: November 19, 2021

The state of the fight: 

U.S. regulators signed off on boosters for all adults.
  India raised a syringe export limit to allow supplies to reach PAHO and UNICEF.
  Pfizer will let Medicines Patent Pool sublicense its oral antiviral to manufacturers in 95 countries.

AUTHORIZED VACCINES  
 

Pfizer/BioNTech’s shot generated stronger antibody responses than three rival vaccines. Comirnaty’s performance bested those of the AstraZeneca/Oxford vaccine, the…

Mentions:
Covid-19, vaccines, drugs, Pfizer, BioNTech, AstraZeneca, Gamaleya Institute, CNBG, Sinopharm, Novavax, SK Bioscience, Moderna, Sinovac, FDA, CDC, CanSino, CureVac, GSK, COVAX, SII, PAHO, UNICEF, Gavi, CEPI, Regeneron, Roche, Lilly, Vir, EMA, Merck, MPP
Read more
Subscribe to MPP